DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Bessemer Group Inc.

Bessemer Group Inc. boosted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 2.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 949,091 shares of the medical device company’s stock after acquiring an additional 25,459 shares during the quarter. Bessemer Group Inc. owned about 0.24% of DexCom worth $64,812,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Private Trust Co. NA grew its stake in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the period. Optiver Holding B.V. purchased a new stake in DexCom during the fourth quarter worth about $33,000. TD Private Client Wealth LLC grew its position in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after buying an additional 167 shares during the period. Larson Financial Group LLC grew its position in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after buying an additional 137 shares during the period. Finally, Heck Capital Advisors LLC purchased a new position in DexCom in the fourth quarter valued at about $38,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Down 3.3%

Shares of NASDAQ DXCM opened at $84.68 on Thursday. The firm has a market cap of $33.20 billion, a P/E ratio of 63.19, a price-to-earnings-growth ratio of 1.87 and a beta of 1.46. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $117.19. The firm’s 50 day moving average price is $81.02 and its 200 day moving average price is $79.50.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. DexCom’s revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.32 EPS. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity

In related news, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction on Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the transaction, the director now owns 56,621 shares in the company, valued at approximately $4,706,903.73. This trade represents a 4.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 10,000 shares of the business’s stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $84.28, for a total value of $842,800.00. Following the sale, the executive vice president now directly owns 95,602 shares of the company’s stock, valued at approximately $8,057,336.56. This trade represents a 9.47% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 25,724 shares of company stock valued at $2,157,034 in the last 90 days. 0.32% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Canaccord Genuity Group boosted their price target on DexCom from $103.00 to $106.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. Citigroup reaffirmed a “buy” rating and set a $102.00 price objective (up from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Wall Street Zen upgraded DexCom from a “hold” rating to a “buy” rating in a research report on Saturday, June 21st. Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Finally, Barclays lifted their price target on DexCom from $90.00 to $93.00 and gave the stock an “equal weight” rating in a research note on Monday, May 5th. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $98.50.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.